Richard J Miron1,2,3, Masako Fujioka-Kobayashi4,5,6, Yufeng Zhang7, Anton Sculean8, Benjamin Pippenger9, Yoshinori Shirakata10, Umadevi Kandalam11, Maria Hernandez4. 1. Department of Periodontology, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. rmiron@nova.edu. 2. Cell Therapy Institute, Center for Collaborative Research, Nova Southeastern University, Fort Lauderdale, FL, USA. rmiron@nova.edu. 3. Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, Ann Arbor, MI, USA. rmiron@nova.edu. 4. Department of Periodontology, College of Dental Medicine, Nova Southeastern University, Fort Lauderdale, FL, USA. 5. Department of Cranio-Maxillofacial Surgery, Bern University Hospital, Inselspital, Bern, Switzerland. 6. Department of Oral Surgery, Clinical Dentistry, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan. 7. Department of Oral Implantology, University of Wuhan, Wuhan, China. 8. Department of Periodontology, University of Bern, Bern, Switzerland. 9. Research Department, Institut Straumann AG, Basel, Switzerland. 10. Department of Periodontology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. 11. Department of Pediatric Dentistry, Nova Southeastern University, Fort Lauderdale, USA.
Abstract
OBJECTIVES: Dimensional changes of the alveolar bone following tooth extraction are a major challenge in daily dental practice. To limit bone loss, a variety of biomaterials including bone grafts, barrier membranes, and growth factors have been utilized either alone or in combination therapies to increase the speed and quality of new bone formation. The aim of the present in vitro study was to investigate the regenerative potential of Osteogain®, a new liquid carrier system of enamel matrix derivative (EMD) in combination with an absorbable collagen sponge (ACS) specifically designed for extraction socket healing. MATERIALS AND METHODS: The potential of ACS was first investigated using ELISA to quantify total amelogenin adsorption and release from 0 to 10 days. Thereafter, the cellular effects of ST2 pre-osteoblasts were investigated for cellular attachment at 8 h and cell proliferation at 1, 3, and 5 days as well as osteoblast differentiation by real-time PCR and alizarin red staining for cells seeded on (1) tissue culture plastic, (2) ACS alone, and (3) ACS + Osteogain®. RESULTS: ACS efficiently loaded nearly 100% of the amelogenin proteins found in Osteogain® which were gradually released up to a 10-day period. Osteogain® also significantly induced a 1.5-fold increase in cell attachment and resulted in a 2-6-fold increase in mRNA levels of osteoblast differentiation markers including runt-related transcription factor 2 (Runx2), collagen1a2, alkaline phosphatase, and bone sialoprotein as well as induced alizarin red staining when combined with ACS. CONCLUSIONS: In summary, these findings suggest that Osteogain® is capable of inducing osteoblast attachment and differentiation when combined with ACS. Future animal studies and randomized human clinical trials are necessary to further support these findings. CLINICAL RELEVANCE: The use of Osteogain® in combination with ACS may provide a valuable means to limit dimensional changes following tooth extraction.
OBJECTIVES: Dimensional changes of the alveolar bone following tooth extraction are a major challenge in daily dental practice. To limit bone loss, a variety of biomaterials including bone grafts, barrier membranes, and growth factors have been utilized either alone or in combination therapies to increase the speed and quality of new bone formation. The aim of the present in vitro study was to investigate the regenerative potential of Osteogain®, a new liquid carrier system of enamel matrix derivative (EMD) in combination with an absorbable collagen sponge (ACS) specifically designed for extraction socket healing. MATERIALS AND METHODS: The potential of ACS was first investigated using ELISA to quantify total amelogenin adsorption and release from 0 to 10 days. Thereafter, the cellular effects of ST2 pre-osteoblasts were investigated for cellular attachment at 8 h and cell proliferation at 1, 3, and 5 days as well as osteoblast differentiation by real-time PCR and alizarin red staining for cells seeded on (1) tissue culture plastic, (2) ACS alone, and (3) ACS + Osteogain®. RESULTS: ACS efficiently loaded nearly 100% of the amelogenin proteins found in Osteogain® which were gradually released up to a 10-day period. Osteogain® also significantly induced a 1.5-fold increase in cell attachment and resulted in a 2-6-fold increase in mRNA levels of osteoblast differentiation markers including runt-related transcription factor 2 (Runx2), collagen1a2, alkaline phosphatase, and bone sialoprotein as well as induced alizarin red staining when combined with ACS. CONCLUSIONS: In summary, these findings suggest that Osteogain® is capable of inducing osteoblast attachment and differentiation when combined with ACS. Future animal studies and randomized human clinical trials are necessary to further support these findings. CLINICAL RELEVANCE: The use of Osteogain® in combination with ACS may provide a valuable means to limit dimensional changes following tooth extraction.
Entities:
Keywords:
Absorbable collagen sponge; Bone regeneration; Enamel matrix derivative; Enamel matrix proteins; Growth factor; Regenerative therapy; Tooth extraction; Tooth loss
Authors: Richard J Miron; Anton Sculean; David L Cochran; Stuart Froum; Giovanni Zucchelli; Carlos Nemcovsky; Nikos Donos; Staale Petter Lyngstadaas; James Deschner; Michel Dard; Andreas Stavropoulos; Yufeng Zhang; Leonardo Trombelli; Adrian Kasaj; Yoshinori Shirakata; Pierpaolo Cortellini; Maurizio Tonetti; Giulio Rasperini; Søren Jepsen; Dieter D Bosshardt Journal: J Clin Periodontol Date: 2016-05-28 Impact factor: 8.728
Authors: Bozidar M B Brkovic; Hari S Prasad; George Konandreas; Radulovic Milan; Dragana Antunovic; George K B Sándor; Michael D Rohrer Journal: J Can Dent Assoc Date: 2008 Jul-Aug Impact factor: 1.316
Authors: Jung Soo Park; Andreas Max Pabst; Maximilian Ackermann; Maximilian Moergel; Junho Jung; Adrian Kasaj Journal: Clin Oral Investig Date: 2017-07-11 Impact factor: 3.573